Nathan Vardi, managing editor at MarketWatch, and author of the new book “For Blood and Money: Billionaires, Biotech, and the Quest for a Blockbuster Drug,” is the guest of honor on today’s show. Nathan divulges on what happened behind closed doors for the creation of BTK inhibitors. Everything at the intersection of Wall Street, investigators, doctors, regulatory agencies, investors, and VC is detailed. He begins by explaining the inspiration to cover this story and how willing individuals were to speak on the record, describes in detail a few of the nuances of and feelings toward specific characters, provides examples of the role that luck plays in cancer drug development, and opines on the FDA’s challenge of approving the right drugs for market, among many other fascinating topics.
Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding
Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. On this Healthcare Unfiltered episode, he explains who may be eligible for these tests, how to interpret results to avoid unnecessary
In this special episode, I give up the microphone to guest host Kelly Ryerson, who takes over the show asking questions about my new book “The Cancer Journey.”
